Aura Biosciences Overview
Aura Biosciences (AURA) has a ROE of -104.8%, below the sector sector average of -4.47%.
Get informed when a big investor buys or sells
+ Follow-104.80%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for AURA is -104.8%. That is below the sector sector average of -4.47%. Investors often review this figure alongside Aura Biosciences's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, AURA currently prints -104.8% for ROE, while the sector average sits near -4.47%. That is roughly 2245.3% below the sector mean. Large gaps often invite a closer look at Aura Biosciences's growth, margins, and balance sheet.
Return on Equity shows how effectively Aura Biosciences converts resources into returns. At -104.8%, AURA may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting AURA's ROE (-104.8%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
